UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

RESILIENT part 1: a phase 2 dose‐exploration and dose‐expansion study of second‐line liposomal irinotecan in adults with small cell lung cancer

Cancer, 2022-05, Vol.128 (9), p.1801-1811

2022

Volltextzugriff (PDF)

Geriatric assessment in clinical practice for patients with stage IV non‐small‐cell lung cancer: The Grup de Investigació I Divulgació Oncològica experience

European journal of cancer care, 2018-11, Vol.27 (6), p.e12950-n/a

2018

Volltextzugriff (PDF)

The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

Clinical & translational oncology, 2024-07, Vol.26 (7), p.1779-1789

2024

Volltextzugriff (PDF)

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2019-12, Vol.20 (12), p.1655-1669

2019

Volltextzugriff (PDF)

Immunogenicity of COVID-19 vaccines in lung cancer patients

Lung cancer (Amsterdam, Netherlands), 2023-10, Vol.184, p.107323-107323, Article 107323

2023

Volltextzugriff (PDF)

Tratamiento con afatinib en primera línea EGFR M+. Resultados según subtipo de mutación

Medicina clínica, 2016-04, Vol.146, p.12-18

Vidal, Óscar Juan

2016

Volltextzugriff (PDF)

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

Journal for immunotherapy of cancer, 2024-02, Vol.12 (2), p.e008189

2024

Volltextzugriff (PDF)

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9501-9501

2020

Volltextzugriff (PDF)

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial

Journal of thoracic oncology, 2017-04, Vol.12 (4), p.752-762

2017

Volltextzugriff (PDF)

nab -Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)

Frontiers in oncology, 2021-02, Vol.10, p.569715-569715

2021

Volltextzugriff (PDF)

Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation

Medicina clinica, 2016-04, Vol.146 Suppl 1, p.12

Vidal, Óscar Juan

2016

Volltextzugriff (PDF)

Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer

Clinical drug investigation, 2024-08, Vol.44 (8), p.553-576

2024

Volltextzugriff (PDF)

Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer

Clinical drug investigation, 2024-08, Vol.44 (8), p.553-576

2024

Volltextzugriff (PDF)

Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC

JTO clinical and research reports, 2023-02, Vol.4 (2), p.100461-100461, Article 100461

2023

Volltextzugriff (PDF)

A real‑world study of clinical characteristics, treatment sequence and outcomes of patients with non-small cell lung cancer and EGFR exon 20 insertion mutations

Clinical & translational oncology, 2024-11

2024

Volltextzugriff (PDF)

Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutations

Cancer letters, 2024-12, Vol.606, p.217317, Article 217317

2024

Volltextzugriff (PDF)

European Society of Medical Oncology (ESMO) guidelines for oncogene-addicted metastatic non-small cell lung cancer (NSCLC): a personalized treatment for each patient

Chinese Clinical Oncology, 2024-06, Vol.13 (3), p.46-46

2024

Volltextzugriff (PDF)

Immune checkpoint inhibitors in special populations. A focus on advanced lung cancer patients

Lung cancer (Amsterdam, Netherlands), 2020-06, Vol.144, p.1-9

2020

Volltextzugriff (PDF)

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

The New England journal of medicine, 2023-11, Vol.389 (22), p.2063-2075

2023

Volltextzugriff (PDF)

1 – 25 von 300

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(265)
Mit Volltextzugriff
(257)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(143)
Life Sciences & Biomedicine
(133)
Humans
(99)
Female
(61)
Male
(57)
Oncology
(44)
Aged
(43)
Middle Aged
(43)
Surgery
(38)
Adult
(31)
Patients
(22)
Lung Cancer
(19)
Lung Neoplasms - Pathology
(18)
Aged, 80 And Over
(16)
Carcinoma, Non-Small-Cell Lung - Pathology
(16)
Prospective Studies
(16)
Spain
(16)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(15)
Chemotherapy
(15)
Lung Neoplasms - Drug Therapy
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

RESILIENT part 1: a phase 2 dose‐exploration and dose‐expansion study of second‐line liposomal irinotecan in adults with small cell lung cancer

Geriatric assessment in clinical practice for patients with stage IV non‐small‐cell lung cancer: The Grup de Investigació I Divulgació Oncològica experience

ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)

The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Immunogenicity of COVID-19 vaccines in lung cancer patients

Tratamiento con afatinib en primera línea EGFR M+. Resultados según subtipo de mutación

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data

Comprehensive cross‐platform comparison of methods for non‐invasive EGFR mutation testing: results of the RING observational trial

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial

nab -Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)

Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation

Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer

Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer

Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC

A real‑world study of clinical characteristics, treatment sequence and outcomes of patients with non-small cell lung cancer and EGFR exon 20 insertion mutations

Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutations

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

European Society of Medical Oncology (ESMO) guidelines for oncogene-addicted metastatic non-small cell lung cancer (NSCLC): a personalized treatment for each patient

Immune checkpoint inhibitors in special populations. A focus on advanced lung cancer patients

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

Suchergebnisse filtern